Back to List View Graph View

Checkpoint inhibitor

Immune checkpoint inhibitors (ICIs), also called immune checkpoint blockade (ICB), are a class of cancer immunotherapy drugs — most often monoclonal antibodies — that block inhibitory receptor–ligand interactions used by tumors to suppress T cell activity.

Where the papers sit

47 papers from the last 6 months study checkpoint inhibitor directly · updated from PubMed 14 Nov 2026

Those 47 are all about one subject.

  • Cancer Immunotherapy in Practice

    Cancer immunotherapy is moving from trial efficacy toward broader, more individualized use across first-line, perioperative and adjuvant care. Recurring priorities include MRI-defined heterogeneity, tumor longevity, PIK3CA selection and circadian timing as predictors of benefit. Combination strategies pair immunotherapy with chemotherapy, TKIs, hyperthermia, microbiota interventions and macrophage-targeting mRNA nanoparticles. Safety, quality of life, transplant complications and management of immune-mediated colitis remain central unresolved issues.

    47 papers

PARADIGM SHIFT

Immune checkpoint inhibitors can retain meaningful benefit in settings considered poor or unsafe candidates for them

The post-allogeneic hematopoietic stem-cell transplantation lung-cancer cohort 42815253Sep and the chemorefractory proficient-mismatch-repair/microsatellite-stable metastatic colorectal cancer comparison 42686374Sep each challenge a different limitation placed on checkpoint inhibitors: uncertain utility with persistent graft-versus-host disease concerns after transplantation, and generally limited efficacy in microsatellite-stable disease. Instead, checkpoint inhibitor–based treatment was associated with longer survival than chemotherapy in advanced non-small-cell lung cancer after transplantation, without a large excess of severe immune toxicity, while ICIs also improved overall survival over standard care in chemorefractory microsatellite-stable colorectal cancer, particularly in patients without liver metastases. Together, these findings shift the frame from treating such contexts as broadly unsuitable to identifying subsets in which checkpoint inhibition remains clinically useful.

NEW DIRECTION

Checkpoint inhibition is used to amplify vaccine- and recall-antigen responses, not only to treat tumors

The healthy-donor and post-immunotherapy patient peripheral-blood mononuclear-cell model tested checkpoint inhibition before exposure to CEF(T), SARS-CoV-2 spike proteins, and ChAdOx1 nCoV-19. Whereas the set otherwise treats checkpoint inhibitors as anticancer treatments or tools for predicting, explaining, or managing their effects, this study found that blockade acutely increased antigen-specific proliferation and cytokine and cytolytic-molecule secretion, including responses to the vaccine platform. This assigns checkpoint inhibition an immunization-enhancing role—as a potential means of strengthening vaccine and recall responses—rather than solely a tumor-directed therapeutic role 42836482Oct.

Papers

The 47 papers from the last 6 months that study checkpoint inhibitor directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Cancer Immunotherapy in Practice (47)
  1. First-line treatment of gastric cancer: Five trials to watch. Med (New York, N.Y.) · 13 Nov 2026 PMID 43025398
  2. Tumor Longevity: a time-dependent biomarker of immune checkpoint inhibitor responsiveness across head and neck, lung, renal and urothelial cancers. The oncologist · 6 Nov 2026 PMID 42992952
  3. Decoding tumor heterogeneity using MRI for predicting response to immune checkpoint inhibitors in hepatocellular carcinoma: a multicenter study. La Radiologia medica · 4 Nov 2026 PMID 42980728
  4. Real-World Evidence of First- or Second-Line Immune Checkpoint Inhibitors Versus Chemotherapy in Advanced NSCLC: A Prospective Pragmatic Multicenter Korean Study. JTO clinical and research reports · 30 Oct 2026 PMID 42960209
  5. Timing between public safety signals and label strengthening in targeted oncology therapies. European journal of clinical pharmacology · 23 Oct 2026 PMID 42918936
  6. Immune checkpoint inhibition enhances memory T-cell responses to CEF(T), SARS-CoV-2 spike proteins and ChAdOx1 nCoV-19. Human vaccines & immunotherapeutics · 6 Oct 2026 PMID 42836482
  7. Lung cancer after allogeneic hematopoietic stem cell transplantation. Lung cancer (Amsterdam, Netherlands) · 30 Sept 2026 PMID 42815253
  8. Efficacy and safety of immune checkpoint inhibitors combined with TKIs for recurrent or metastatic cervical cancer with PIK3CA mutation. PloS one · 29 Sept 2026 PMID 42809552
  9. Efficacy and safety of radiofrequency hyperthermia combined with immune checkpoint inhibitors and chemotherapy as first-line treatment for HER2-negative advanced gastric/gastroesophageal junction adenocarcinoma: A propensity score-matched study. Human vaccines & immunotherapeutics · 28 Sept 2026 PMID 42803704
  10. Surgical safety of preoperative or perioperative immune checkpoint inhibitors in colorectal cancer surgery: protocol for a systematic review and meta-analysis focusing on anastomotic leakage. BMJ open · 25 Sept 2026 PMID 42790910
  11. Circadian timing of first-line chemoimmunotherapy is associated with survival in extensive-stage small cell lung cancer. Oncoimmunology · 25 Sept 2026 PMID 42788839
  12. Health-related quality of life with adjuvant immune checkpoint inhibition in renal cell carcinoma: A qualitative study of UK participants in the phase III RAMPART trial. PloS one · 21 Sept 2026 PMID 42766600
  13. Chronotherapy with immune checkpoint inhibitors: The knowns, the unknowns, and the contested. Cancer cell · 15 Sept 2026 PMID 42743928
  14. Targeting the ChREBP/PKLR-lactate axis via Huachansu tablets restores CD8⁺T cell immunity in MASH-HCC. Pharmacological research · 14 Sept 2026 PMID 42735733
  15. First-line fecal microbiota transplantation for the management of immune checkpoint inhibitor-mediated diarrhea and colitis. Cell reports. Medicine · 14 Sept 2026 PMID 42735684
  16. Targeting tumor-associated macrophages using mRNA lipid nanoparticles for cytotoxic T lymphocyte-mediated cancer immunotherapy. Science advances · 11 Sept 2026 PMID 42726873
  17. Decondensing cancer immunotherapy. Science (New York, N.Y.) · 10 Sept 2026 PMID 42721256
  18. Overall survival of immunotherapy versus standard of care in chemorefractory microsatellite stable metastatic colorectal cancer: a propensity score matched analysis of 708 patients. Journal for immunotherapy of cancer · 2 Sept 2026 PMID 42686374
  19. Tumor immune microenvironment remodeling predicts response to checkpoint inhibitor therapy. Cancer cell · 1 Sept 2026 PMID 42679812
  20. TIME in motion: How response takes shape. Cancer cell · 1 Sept 2026 PMID 42679809
  21. Cardiac tertiary immune niches drive immune activation in immune checkpoint inhibitor myocarditis. Science advances · 26 Aug 2026 PMID 42647623
  22. Melanoma to rhabdomyosarcoma plasticity in the setting of immunotherapy. Med (New York, N.Y.) · 20 Aug 2026 PMID 42624103
  23. Timing of Immune Checkpoint Inhibitor Initiation and Overall Survival in Advanced Gastric Cancer: A Multicenter Real-World Study Using Clone-Censor-Weight Analysis. Journal of gastrointestinal cancer · 13 Aug 2026 PMID 42593634
  24. A stromal-immune computational pathology signature for prognosis and immune checkpoint inhibitor response in localized, locally advanced and metastatic urothelial carcinoma: A multicenter retrospective study. European journal of cancer (Oxford, England : 1990) · 12 Aug 2026 PMID 42585992
  25. Complex bifurcation dynamics of tumor-immune interactions incorporating combination therapies. Journal of mathematical biology · 7 Aug 2026 PMID 42562918
  26. Machine learning approaches to predict early cardiac immune-related adverse events in patients receiving immune checkpoint inhibitors. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 28 Jul 2026 PMID 42521802
  27. Quantitative calibration of a spatial QSP model identifies fibroblast impact on HCC immunotherapy. Proceedings of the National Academy of Sciences of the United States of America · 14 Jul 2026 PMID 42446991
  28. Enhanced anti-tumor effects of Imatinib and immune checkpoint inhibitors on gastrointestinal stromal tumor cells (GISTs): insights from monoculture and 3D co-culture models. Medical oncology (Northwood, London, England) · 13 Jul 2026 PMID 42439972
  29. The Impact of Immunotherapy on Hair Repigmentation in Patients With Thoracic Tumors: A Clinical Observation Based on Trichoscopy. Thoracic cancer · 1 Jul 2026 PMID 42387269
  30. Camrelizumab, Apatinib, and Radiotherapy in Locally Advanced, Unresectable Hepatocellular Carcinoma: A Phase II Study. Clinical cancer research : an official journal of the American Association for Cancer Research · 30 Jun 2026 PMID 42377073
  31. OpenIO: An open framework for AI-native immunotherapy. Cancer cell · 25 Jun 2026 PMID 42349428
  32. Impact of preexisting interstitial lung disease on pneumonitis and survival during first-line immune checkpoint inhibitor-based therapy in non-small cell lung cancer. European journal of cancer (Oxford, England : 1990) · 25 Jun 2026 PMID 42349343
  33. Blood-based kinase activity profiling to predict response to immune checkpoint inhibitors in patients with advanced stage NSCLC: the prospective IOpener study. Journal for immunotherapy of cancer · 24 Jun 2026 PMID 42342406
  34. Immune checkpoint inhibitor neurotoxicity: long-term outcomes with focus on 1-year neurological sequelae. Journal for immunotherapy of cancer · 24 Jun 2026 PMID 42342405
  35. Magnetic resonance imaging radiomic phenotypes stratify response and define immune states in very high-risk, nonmuscle-invasive bladder cancer treated with tislelizumab plus nanoparticle albumin-bound paclitaxel. Cancer · 24 Jun 2026 PMID 42339693
  36. Cancer Chemoimmunotherapy: Time Will Tell. Cancer immunology research · 8 Jun 2026 PMID 42258320
  37. Oncological outcome and immune-checkpoint-blockade-induced toxicities in patients with cervical cancer - a Norwegian real-world cohort. Acta oncologica (Stockholm, Sweden) · 1 Jun 2026 PMID 42220011
  38. Time of day of neoadjuvant immune checkpoint inhibitor administration is associated with survival but not pathological response in resectable stage III-IV melanoma: A retrospective cohort study. European journal of cancer (Oxford, England : 1990) · 30 May 2026 PMID 42218102
  39. A real-world data analysis of the impact of clonal hematopoiesis of indeterminate potential on therapeutic efficacy and adverse events of immune checkpoint inhibitors. Cancer · 30 May 2026 PMID 42216432
  40. Treatment and outcomes of immunotherapy related colitis and hepatitis- a multi-centre cohort study in the United Kingdom by the National Oncology Trainee Collaborative for Healthcare Research (NOTCH). Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 29 May 2026 PMID 42213142
  41. AI-based histopathology analysis predicts checkpoint inhibitor response in advanced melanoma and identifies patterns associated with response. European journal of cancer (Oxford, England : 1990) · 28 May 2026 PMID 42208280
  42. Beneficial Effects of Combining an Immune Checkpoint Inhibitor With Proton Radiation, OXi4503, or Hyperthermia in a Murine Solid Tumor Model. Anticancer research · 27 May 2026 PMID 42203349
  43. Molecular architecture of the tumor microenvironment caused by BRCA1 and BRCA2 somatic mutations in human lung adenocarcinoma. eLife · 26 May 2026 PMID 42189716
  44. Impact of lymph node dissection on survival outcomes in gastric cancer patients receiving immune checkpoint inhibitors. Medicine · 23 May 2026 PMID 42175430
  45. Distinct immune landscapes characterize highly versus minimally invasive brain metastases. JCI insight · 22 May 2026 PMID 42171608
  46. Broadening activity of checkpoint blockade agents by intratumoral nucleoside cleavage. JCI insight · 22 May 2026 PMID 42171604
  47. Early adjunct anti-PD-L1 immunotherapy improves outcomes and restores infection-induced immune paralysis in mice with invasive pulmonary mucormycosis. Proceedings of the National Academy of Sciences of the United States of America · 20 May 2026 PMID 42160348

By study type

Clinical trials (2)
  1. Health-related quality of life with adjuvant immune checkpoint inhibition in renal cell carcinoma: A qualitative study of UK participants in the phase III RAMPART trial. PloS one · 21 Sept 2026 PMID 42766600
  2. Camrelizumab, Apatinib, and Radiotherapy in Locally Advanced, Unresectable Hepatocellular Carcinoma: A Phase II Study. Clinical cancer research : an official journal of the American Association for Cancer Research · 30 Jun 2026 PMID 42377073
Observational studies and case reports (18)
  1. Efficacy and safety of immune checkpoint inhibitors combined with TKIs for recurrent or metastatic cervical cancer with PIK3CA mutation. PloS one · 29 Sept 2026 PMID 42809552
  2. Efficacy and safety of radiofrequency hyperthermia combined with immune checkpoint inhibitors and chemotherapy as first-line treatment for HER2-negative advanced gastric/gastroesophageal junction adenocarcinoma: A propensity score-matched study. Human vaccines & immunotherapeutics · 28 Sept 2026 PMID 42803704
  3. Circadian timing of first-line chemoimmunotherapy is associated with survival in extensive-stage small cell lung cancer. Oncoimmunology · 25 Sept 2026 PMID 42788839
  4. Overall survival of immunotherapy versus standard of care in chemorefractory microsatellite stable metastatic colorectal cancer: a propensity score matched analysis of 708 patients. Journal for immunotherapy of cancer · 2 Sept 2026 PMID 42686374
  5. Melanoma to rhabdomyosarcoma plasticity in the setting of immunotherapy. Med (New York, N.Y.) · 20 Aug 2026 PMID 42624103
  6. Timing of Immune Checkpoint Inhibitor Initiation and Overall Survival in Advanced Gastric Cancer: A Multicenter Real-World Study Using Clone-Censor-Weight Analysis. Journal of gastrointestinal cancer · 13 Aug 2026 PMID 42593634
  7. A stromal-immune computational pathology signature for prognosis and immune checkpoint inhibitor response in localized, locally advanced and metastatic urothelial carcinoma: A multicenter retrospective study. European journal of cancer (Oxford, England : 1990) · 12 Aug 2026 PMID 42585992
  8. Machine learning approaches to predict early cardiac immune-related adverse events in patients receiving immune checkpoint inhibitors. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 28 Jul 2026 PMID 42521802
  9. The Impact of Immunotherapy on Hair Repigmentation in Patients With Thoracic Tumors: A Clinical Observation Based on Trichoscopy. Thoracic cancer · 1 Jul 2026 PMID 42387269
  10. Impact of preexisting interstitial lung disease on pneumonitis and survival during first-line immune checkpoint inhibitor-based therapy in non-small cell lung cancer. European journal of cancer (Oxford, England : 1990) · 25 Jun 2026 PMID 42349343
  11. Blood-based kinase activity profiling to predict response to immune checkpoint inhibitors in patients with advanced stage NSCLC: the prospective IOpener study. Journal for immunotherapy of cancer · 24 Jun 2026 PMID 42342406
  12. Magnetic resonance imaging radiomic phenotypes stratify response and define immune states in very high-risk, nonmuscle-invasive bladder cancer treated with tislelizumab plus nanoparticle albumin-bound paclitaxel. Cancer · 24 Jun 2026 PMID 42339693
  13. Oncological outcome and immune-checkpoint-blockade-induced toxicities in patients with cervical cancer - a Norwegian real-world cohort. Acta oncologica (Stockholm, Sweden) · 1 Jun 2026 PMID 42220011
  14. Time of day of neoadjuvant immune checkpoint inhibitor administration is associated with survival but not pathological response in resectable stage III-IV melanoma: A retrospective cohort study. European journal of cancer (Oxford, England : 1990) · 30 May 2026 PMID 42218102
  15. A real-world data analysis of the impact of clonal hematopoiesis of indeterminate potential on therapeutic efficacy and adverse events of immune checkpoint inhibitors. Cancer · 30 May 2026 PMID 42216432
  16. Treatment and outcomes of immunotherapy related colitis and hepatitis- a multi-centre cohort study in the United Kingdom by the National Oncology Trainee Collaborative for Healthcare Research (NOTCH). Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 29 May 2026 PMID 42213142
  17. AI-based histopathology analysis predicts checkpoint inhibitor response in advanced melanoma and identifies patterns associated with response. European journal of cancer (Oxford, England : 1990) · 28 May 2026 PMID 42208280
  18. Impact of lymph node dissection on survival outcomes in gastric cancer patients receiving immune checkpoint inhibitors. Medicine · 23 May 2026 PMID 42175430
Human data, design not indexed (10)
  1. First-line treatment of gastric cancer: Five trials to watch. Med (New York, N.Y.) · 13 Nov 2026 PMID 43025398
  2. Timing between public safety signals and label strengthening in targeted oncology therapies. European journal of clinical pharmacology · 23 Oct 2026 PMID 42918936
  3. Immune checkpoint inhibition enhances memory T-cell responses to CEF(T), SARS-CoV-2 spike proteins and ChAdOx1 nCoV-19. Human vaccines & immunotherapeutics · 6 Oct 2026 PMID 42836482
  4. Lung cancer after allogeneic hematopoietic stem cell transplantation. Lung cancer (Amsterdam, Netherlands) · 30 Sept 2026 PMID 42815253
  5. Surgical safety of preoperative or perioperative immune checkpoint inhibitors in colorectal cancer surgery: protocol for a systematic review and meta-analysis focusing on anastomotic leakage. BMJ open · 25 Sept 2026 PMID 42790910
  6. Tumor immune microenvironment remodeling predicts response to checkpoint inhibitor therapy. Cancer cell · 1 Sept 2026 PMID 42679812
  7. Quantitative calibration of a spatial QSP model identifies fibroblast impact on HCC immunotherapy. Proceedings of the National Academy of Sciences of the United States of America · 14 Jul 2026 PMID 42446991
  8. Immune checkpoint inhibitor neurotoxicity: long-term outcomes with focus on 1-year neurological sequelae. Journal for immunotherapy of cancer · 24 Jun 2026 PMID 42342405
  9. Cancer Chemoimmunotherapy: Time Will Tell. Cancer immunology research · 8 Jun 2026 PMID 42258320
  10. Molecular architecture of the tumor microenvironment caused by BRCA1 and BRCA2 somatic mutations in human lung adenocarcinoma. eLife · 26 May 2026 PMID 42189716
Preclinical: animal, cell and lab studies (12)
  1. Chronotherapy with immune checkpoint inhibitors: The knowns, the unknowns, and the contested. Cancer cell · 15 Sept 2026 PMID 42743928
  2. Targeting tumor-associated macrophages using mRNA lipid nanoparticles for cytotoxic T lymphocyte-mediated cancer immunotherapy. Science advances · 11 Sept 2026 PMID 42726873
  3. Decondensing cancer immunotherapy. Science (New York, N.Y.) · 10 Sept 2026 PMID 42721256
  4. TIME in motion: How response takes shape. Cancer cell · 1 Sept 2026 PMID 42679809
  5. Cardiac tertiary immune niches drive immune activation in immune checkpoint inhibitor myocarditis. Science advances · 26 Aug 2026 PMID 42647623
  6. Complex bifurcation dynamics of tumor-immune interactions incorporating combination therapies. Journal of mathematical biology · 7 Aug 2026 PMID 42562918
  7. Enhanced anti-tumor effects of Imatinib and immune checkpoint inhibitors on gastrointestinal stromal tumor cells (GISTs): insights from monoculture and 3D co-culture models. Medical oncology (Northwood, London, England) · 13 Jul 2026 PMID 42439972
  8. OpenIO: An open framework for AI-native immunotherapy. Cancer cell · 25 Jun 2026 PMID 42349428
  9. Beneficial Effects of Combining an Immune Checkpoint Inhibitor With Proton Radiation, OXi4503, or Hyperthermia in a Murine Solid Tumor Model. Anticancer research · 27 May 2026 PMID 42203349
  10. Distinct immune landscapes characterize highly versus minimally invasive brain metastases. JCI insight · 22 May 2026 PMID 42171608
  11. Broadening activity of checkpoint blockade agents by intratumoral nucleoside cleavage. JCI insight · 22 May 2026 PMID 42171604
  12. Early adjunct anti-PD-L1 immunotherapy improves outcomes and restores infection-induced immune paralysis in mice with invasive pulmonary mucormycosis. Proceedings of the National Academy of Sciences of the United States of America · 20 May 2026 PMID 42160348
Unclassified: not yet indexed with MeSH (5)
  1. Tumor Longevity: a time-dependent biomarker of immune checkpoint inhibitor responsiveness across head and neck, lung, renal and urothelial cancers. The oncologist · 6 Nov 2026 PMID 42992952
  2. Decoding tumor heterogeneity using MRI for predicting response to immune checkpoint inhibitors in hepatocellular carcinoma: a multicenter study. La Radiologia medica · 4 Nov 2026 PMID 42980728
  3. Real-World Evidence of First- or Second-Line Immune Checkpoint Inhibitors Versus Chemotherapy in Advanced NSCLC: A Prospective Pragmatic Multicenter Korean Study. JTO clinical and research reports · 30 Oct 2026 PMID 42960209
  4. Targeting the ChREBP/PKLR-lactate axis via Huachansu tablets restores CD8⁺T cell immunity in MASH-HCC. Pharmacological research · 14 Sept 2026 PMID 42735733
  5. First-line fecal microbiota transplantation for the management of immune checkpoint inhibitor-mediated diarrhea and colitis. Cell reports. Medicine · 14 Sept 2026 PMID 42735684